Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or
dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and …

The aims of severe perioperative bleeding management are three-fold. First, preoperative
identification by anamesis and laboratory testing of those patients for whom the …

Background The development of neutralizing anti–factor VIII alloantibodies (inhibitors) in
patients with severe hemophilia A may depend on the concentrate used for replacement …

Background For previously untreated children with severe hemophilia A, it is unclear
whether the type of factor VIII product administered and switching among products are …

Background—Periprocedural bridging with unfractionated heparin or low-molecular-weight
heparin aims to reduce the risk of thromboembolic events in patients receiving long-term …

A normal hemostatic response to vascular injury requires both factor VIII (FVIII) and von
Willebrand factor (VWF). In plasma, VWF and FVIII normally circulate as a noncovalent …

Over the past forty years the availability of coagulation factor replacement therapy has
greatly contributed to the improved care of people with hemophilia. Following the blood …

Factor VIII (FVIII) replacement therapy is the foundation of treatment in hemophilia A and is
effective unless a patient develops an alloantibody (inhibitor) against exogenous FVIII …

Hemophilia A is an X-linked hereditary bleeding disorder due to the deficiency of
coagulation factor VIII (FVIII). According to the degree of FVIII deficiency, mild, moderate or …

1School of Medicine, Cardiff University, University Hospital of Wales, Wales, 2Royal
Hospital for Sick Children, Glasgow, 3The London School of Medicine and Dentistry, Royal …